Diuretics — Loop, Thiazide, Potassium-Sparing
Contents (6)
Diuretics are pharmacologic agents that enhance renal excretion of sodium and water by interfering with tubular reabsorption mechanisms, forming the cornerstone of volume management in hypertension, heart failure, edema, and ascites. The major classes—loop diuretics, thiazide diuretics, and potassium-sparing diuretics—differ fundamentally in their sites of action along the nephron, potency, and electrolyte effects, requiring nuanced clinical selection. Loop diuretics (furosemide, torsemide, bumetanide) are most potent and essential in acute decompensation and renal dysfunction, thiazides (hydrochlorothiazide, chlorthalidone) are preferred for chronic hypertension management, and potassium-sparing agents (spironolactone, amiloride) prevent hypokalemia and provide unique mortality benefits in heart failure. Understanding their distinct mechanisms, adverse effects, and drug-drug interactions is critical for safe, effective volume and electrolyte management across the spectrum of internal medicine. Their role in contemporary therapy has evolved with evidence-based medicine, particularly regarding thiazide choice and potassium-sparing agent benefits in systolic heart failure and resistant hypertension.
Loop Diuretics: Site of Action and Mechanism
Loop diuretics (furosemide, torsemide, bumetanide) act on the thick ascending limb of the loop of Henle by inhibiting the Na-K-2Cl cotransporter (NKCC2), blocking the symporter that normally reabsorbs approximately 25% of filtered sodium. This transporter couples the energy of the inward sodium gradient to active transport of potassium and chloride. By blocking this transporter, loop diuretics directly prevent the normal positive electrical potential in the loop lumen that drives paracellular reabsorption of divalent cations (calcium and magnesium). Loop diuretics are "high-ceiling" diuretics—their natriuretic effect continues even at maximal urine osmolality because they block active transport rather than osmotic forces, distinguishing them from thiazides. The result is profound sodium, chloride, and water excretion (10-25% of filtered sodium), accompanied by loss of potassium (due to increased delivery to collecting duct and aldosterone activation), calcium, and magnesium. Loop diuretics also increase renal perfusion pressure acutely, further enhancing diuresis, and stimulate renin-angiotensin-aldosterone system (RAAS) activation as a compensatory response to volume depletion.
Thiazide Diuretics: Mechanism and Sodium Reabsorption Impact
Thiazides (hydrochlorothiazide, chlorthalidone, indapamide) inhibit the Na-Cl cotransporter (NCC) in the early distal convoluted tubule, blocking reabsorption of approximately 5-10% of filtered sodium. Unlike loop diuretics, thiazides are "ceiling" diuretics—their natriuretic effect plateaus at submaximal urine osmolality, limiting their utility in severe renal dysfunction or acute pulmonary edema. However, they possess a paradoxical hypercalciuric effect: by blocking the voltage-dependent calcium channel that normally reabsorbs calcium paracellularly in the early distal tubule (dependent on the positive lumen potential created by potassium secretion), thiazides actually reduce urinary calcium excretion despite causing overall volume depletion. This occurs because volume contraction stimulates proximal tubule calcium reabsorption more potently than the distal effect. Thiazides cause hypokalemia through increased sodium delivery to the collecting duct, enhancing potassium secretion via principal cells. They also activate RAAS, increase uric acid reabsorption (risk of gout), impair glucose metabolism (hyperglycemia), and raise lipid levels through direct pancreatic effects and RAAS activation.
Potassium-Sparing Diuretics: Aldosterone Antagonism and ENaC Blockade
Potassium-sparing diuretics function through two distinct mechanisms: aldosterone antagonists (spironolactone, eplerenone) and epithelial sodium channel (ENaC) blockers (amiloride, triamterene). Aldosterone antagonists competitively inhibit mineralocorticoid receptor binding in the collecting duct principal cells, preventing aldosterone-mediated upregulation of ENaC and Na-K-ATPase. This reduces sodium reabsorption and potassium secretion at the collecting duct, the final opportunity for sodium reabsorption (responsible for only 2-3% of filtered sodium). By blocking aldosterone, these agents also prevent aldosterone's deleterious effects on cardiac and vascular fibrosis, providing unique mortality benefits in systolic heart failure independent of their modest diuretic effect. ENaC blockers directly block the apical sodium channel in principal cells, achieving potassium-sparing diuresis without hormonal dependence. Both classes increase serum potassium concentration and reduce urinary calcium excretion (though less dramatically than thiazides). Potassium-sparing agents synergize with loop and thiazide diuretics by counteracting their kaliuretic effects, but monotherapy produces minimal natriuresis compared to loop or thiazide agents.
Osmotic and Proximal Tubule Effects
All diuretics increase proximal tubule delivery of sodium and water, triggering glomerulotubular balance responses that partially offset their effects. Loop and thiazide diuretics also increase urinary osmolality initially, enhancing water excretion beyond sodium reabsorption effects. At the proximal tubule, increased peritubular capillary oncotic pressure from volume depletion and increased filtration fraction enhance proximal reabsorption of sodium bicarbonate, leading to metabolic alkalosis—a hallmark complication of chronic loop and thiazide diuretic use.
RAAS Activation and Hemodynamic Compensation
All diuretics activate the RAAS through volume depletion-mediated juxtaglomerular apparatus stimulation, increasing angiotensin II and aldosterone production. This causes afferent arteriolar vasoconstriction, prerenal azotemia, and further kaliuresis. In heart failure, this RAAS activation opposes the beneficial hemodynamic effects of diuretics, justifying concurrent ACE inhibitor or angiotensin receptor blocker therapy. Potassium-sparing agents, particularly aldosterone antagonists, directly counteract aldosterone's effects, explaining their synergy with RAAS inhibitors.
Clinical Indications for Diuretic Therapy
Loop Diuretics—Primary Indications:
- Acute decompensated heart failure (HF) with volume overload, pulmonary edema, or orthopnea: loop diuretics are first-line for rapid symptom relief and are the only diuretics capable of negative intravascular volume balance in acute HF
- Chronic systolic heart failure with signs of congestion (reduced ejection fraction [EF] ≤40%): loop diuretics improve symptoms and exercise tolerance, though no mortality benefit has been demonstrated
- Advanced chronic kidney disease (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m²) or acute kidney injury (AKI): thiazides lose efficacy and loop diuretics become mandatory for volume management
- Severe hypertension (systolic BP >180 mmHg) with pulmonary edema or acute coronary syndrome: loop diuretics provide rapid volume reduction
- Nephrotic syndrome with edema: loop diuretics combined with albumin infusion in acute settings
- Cirrhosis with ascites: loop diuretics with aldosterone antagonists are standard therapy
- Pulmonary edema from any cause: acute presentation requiring rapid natriuresis
Thiazide Diuretics—Primary Indications:
- Hypertension in stages 1-2 (systolic BP 130-159 or diastolic BP 80-99 mmHg) without fluid overload: thiazides are guideline-recommended first-line monotherapy, particularly chlorthalidone (longer acting, 12-72 hour half-life) or indapamide over HCTZ (8-hour half-life)
- Chronic kidney disease stage 3-4 without symptomatic fluid overload: thiazides maintain efficacy better than loop diuretics at moderately reduced GFR
- Hypercalciuria management: thiazides paradoxically reduce urinary calcium, beneficial in patients with recurrent calcium kidney stones
- Osteoporosis prevention: chronic thiazide use (especially chlorthalidone) reduces hip fracture risk through increased serum and bone calcium
Potassium-Sparing Diuretics—Primary Indications:
- Systolic heart failure (EF ≤40%) with aldosterone antagonists (spironolactone RALES trial, eplerenone EMPHASIS-HF trial): mortality reduction of 30% in advanced HF, mortality reduction of 27% in post-MI HF with reduced EF—unique indication among diuretics
- Resistant hypertension (BP uncontrolled on 3 antihypertensives including diuretic): spironolactone addition achieves BP control in 50% of resistant hypertension patients
- Cirrhosis with ascites and hypokalemia: first-line diuretic choice as monotherapy or with loop diuretics
- Hypokalemia prevention during chronic loop or thiazide diuretic therapy: potassium-sparing agents prevent hypokalemia-related arrhythmias
- Primary hyperaldosteronism: spironolactone is definitive medical therapy when surgery is contraindicated
Risk Factors and Patient Selection Considerations
- Renal function status: loop diuretics mandatory if eGFR <30; thiazides lose efficacy; potassium-sparing agents require careful monitoring if eGFR <30 to prevent hyperkalemia
- Underlying cardiac rhythm: hypokalemia from loop/thiazide diuretics increases arrhythmia risk in patients with QT prolongation, HF, or concurrent digoxin use
- Comorbid conditions: diabetes (thiazides worsen glucose control), gout (thiazides elevate uric acid), hypercalcemia (loop diuretics preferred), hyperlipidemia (thiazides worsen dyslipidemia), liver disease (potassium-sparing agents preferred)
- Electrolyte abnormalities at baseline: hyperkalemia contraindicates potassium-sparing agents; hypokalemia should prompt combination therapy with potassium-sparing agents
- Concurrent medications: ACE inhibitors/ARBs synergize with potassium-sparing agents (hyperkalemia risk); NSAIDs reduce diuretic efficacy and increase AKI risk
Intended Effects and Patient Goals
- Decreased dyspnea: relief of pulmonary edema manifests as rapid (within hours of IV loop diuretic) improvement in orthopnea and paroxysmal nocturnal dyspnea
- Reduced peripheral edema: gravity-dependent lower extremity swelling decreases over days with chronic diuretic therapy; abdominal edema and ascites resolve more slowly
- Improved exercise tolerance: patients report less fatigue and dyspnea with exertion once euvolemia is restored
- Decreased blood pressure: thiazide and loop diuretics lower BP 10-15 mmHg through volume depletion; aldosterone antagonists add 5-10 mmHg reduction
Adverse Effects from Electrolyte Disturbances
Hypokalemia (Loop and Thiazide Diuretics):
- Symptoms: muscle weakness, fatigue, palpitations (due to hypokalemia-induced automaticity), constipation
- ECG findings: flattened T wave, prominent U wave (classic), ST depression, prolonged QT interval
- Cardiac risk: increases risk of ventricular arrhythmias, particularly in concurrent digoxin use (narrow therapeutic index), HF with reduced EF, or structural heart disease
- Mechanism: increased sodium delivery to collecting duct and aldosterone-mediated potassium secretion
Hyperkalemia (Potassium-Sparing Diuretics):
- Symptoms: often asymptomatic until severe (K >6.5 mEq/L); muscle weakness, paresthesias, cardiac palpitations
- ECG findings: peaked T waves (K >6.5), loss of P wave, widened QRS (K >7.5), sine wave pattern (K >8)—life-threatening
- Risk amplification: markedly increased when combined with ACE inhibitors/ARBs, NSAIDs, or in renal insufficiency (eGFR <30)
- Mechanism: reduced potassium secretion in collecting duct due to aldosterone antagonism or ENaC blockade
Hyponatremia:
- Occurs particularly with: loop diuretics in advanced HF where ADH secretion increases from hypotension and increased sympathetic tone
- Symptoms: nausea, confusion, headache, seizures (if severe and acute), lethargy
- Risk groups: elderly patients, those with SIADH, liver disease, or pulmonary disease
Hypocalcemia and Hypomagnesemia (Loop Diuretics):
- Loop diuretic-specific effect: blocks paracellular divalent cation reabsorption in thick ascending limb
- Symptoms: muscle cramps, paresthesias, tetany, Chvostek and Trousseau signs in severe cases
- Cardiac significance: hypomagnesemia impairs cardiac repolarization, increasing digoxin toxicity and arrhythmia risk
- Thiazide paradox: cause hypercalcemia (not hypocalcemia) through mechanism described in pathophysiology
Hypercalcemia (Thiazide Diuretics):
- Occurs in patients with: hyperparathyroidism, immobility, or high baseline calcium
- Symptoms: polyuria (nephrogenic DI), polydipsia, constipation, cognitive changes
- Significance: thiazides contraindicated in hypercalcemia or hyperparathyroidism; loop diuretics are preferred in such cases
Metabolic Complications
Metabolic Alkalosis:
- Classic presentation: occurs in chronic loop and thiazide diuretic users
- Mechanism: volume depletion increases proximal reabsorption of bicarbonate; hypokalemia drives H+ secretion in collecting duct (renal adaptation)
- Clinical significance: causes paradoxical hypokalemia perpetuation; correction requires both volume repletion and potassium replacement
- Severity markers: pH >7.55, HCO3 >35 mEq/L constitute severe alkalosis requiring ICU monitoring
Metabolic Acidosis:
- Occurs with: potassium-sparing diuretics, particularly in renal insufficiency
- Mechanism: hyperkalemia-induced suppression of ammonia production reduces renal acid excretion
- Severity assessment: pH <7.30 and K >6 constitute medical emergency
Hyperglycemia (Thiazide Diuretics):
- Mechanism: dual effect—direct pancreatic beta-cell suppression (hypokalemia worsens) and insulin resistance from RAAS activation
- Clinical significance: glucose elevation 5-10 mg/dL common; problematic in diabetics, may require intensified hypoglycemic therapy
- Incidence: up to 25% in chronic thiazide users, dose-dependent
Hyperuricemia and Gout (Loop and Thiazide Diuretics):
- Loop diuretics: increase serum uric acid 1-3 mg/dL through volume depletion-induced reduction in glomerular filtration and increased proximal reabsorption
- Thiazides: even greater effect through direct inhibition of urate secretion in proximal tubule
- Clinical significance: precipitate acute gout in 1-2% of treated patients; absolute contraindication in history of gout
Dyslipidemia (Thiazide Diuretics):
- Mechanism: RAAS activation increases hepatic VLDL production; hyperglycemia worsens dyslipidemia
- Changes: LDL cholesterol increase 10-20%, triglyceride increase 10-15%, HDL cholesterol decrease 5%
- Dose-dependency: greater at higher thiazide doses (HCTz ≥25 mg/day)
Volume Depletion and Hemodynamic Manifestations
- **Orthostatic hypotension and
Class-specific toxicities beyond electrolytes
- Ototoxicity (loop diuretics): dose-related, usually reversible tinnitus/hearing loss from NKCC1 inhibition in the stria vascularis, which disrupts endolymph potassium secretion. Risk rises with rapid IV push, high doses, renal failure, and co-administration of aminoglycosides or cisplatin — infuse slowly. Ethacrynic acid is classically described as the most ototoxic loop agent.
- Sulfonamide hypersensitivity: furosemide, bumetanide, torsemide, thiazides, and acetazolamide all carry a sulfonamide moiety. Ethacrynic acid is the non-sulfonamide loop diuretic and is the board-expected substitute, though true cross-reactivity between non-antibiotic sulfonamides and sulfa antibiotics is now considered low.
- Antiandrogen effects (spironolactone): off-target antagonism of androgen and agonism of progesterone receptors causes gynecomastia, breast tenderness, erectile dysfunction, and menstrual irregularity. Eplerenone is receptor-selective and spares these effects.
- Triamterene: poorly soluble metabolites can precipitate as urinary crystals/stones and cause interstitial nephritis.
- Thiazides: photosensitivity, drug-induced pancreatitis, and rare severe hyponatremia in thin elderly women within weeks of starting therapy.
Interactions that create toxicity
- Digoxin: diuretic-induced hypokalemia and hypomagnesemia lower the threshold for digoxin toxicity because digoxin and K+ compete at the Na-K-ATPase.
- Lithium: thiazides increase proximal lithium reabsorption during volume contraction, precipitating lithium toxicity.
- NSAIDs: blunt prostaglandin-mediated afferent vasodilation and renin release, reducing diuretic efficacy and raising AKI risk.
Monitoring and contraindications
- Check a basic metabolic panel and creatinine before and shortly after initiation or dose escalation; the ACC/AHA heart failure guideline specifically directs potassium and renal function surveillance after starting or up-titrating an MRA, with avoidance when potassium is elevated or eGFR is markedly reduced.
- Avoid loop diuretics in anuria; avoid thiazides in symptomatic hypercalcemia; avoid spironolactone in pregnancy (antiandrogen feminization of a male fetus).
Reversal
- Hyperkalemia: IV calcium gluconate for membrane stabilization when ECG changes are present, then insulin with dextrose and a beta-2 agonist to shift potassium intracellularly, then removal (loop diuretic, potassium binder such as patiromer or sodium zirconium cyclosilicate, or dialysis).
- Digoxin toxicity: digoxin immune Fab.
- Symptomatic hyponatremia: hypertonic 3% saline, with the correction rate capped (generally about 8 mEq/L per 24 hours) to prevent osmotic demyelination syndrome.
- Sulfa allergy stem: a patient needing a loop diuretic with documented sulfonamide hypersensitivity gets ethacrynic acid — the only loop agent without a sulfonamide group.
- Calcium is the discriminator: loops lose calcium (hypocalciuria is not their effect — they are adjunctive in hypercalcemia after volume repletion), while thiazides retain calcium, making them the diuretic of choice for recurrent calcium-containing nephrolithiasis with hypercalciuria.
- Gynecomastia in a heart failure patient on spironolactone: the single best next step is switching to eplerenone, which lacks androgen-receptor affinity. Do not stop mineralocorticoid antagonism altogether — the ACC/AHA/HFSA heart failure guideline lists MRAs among the four pillars of guideline-directed therapy for HFrEF alongside an ARNI (or ACEI/ARB), a beta blocker, and an SGLT2 inhibitor.
- Channelopathy mimics are the association examiners love: Bartter syndrome mimics chronic loop diuretic use (NKCC2 defect, hypokalemic metabolic alkalosis, hypercalciuria), and Gitelman syndrome mimics thiazide use (NCC defect, hypokalemic alkalosis with hypocalciuria and hypomagnesemia). A surreptitious diuretic user is distinguished by a urine diuretic screen.
- Thiazides for hypertension: the 2017 ACC/AHA hypertension guideline favors chlorthalidone over hydrochlorothiazide for its longer duration and outcome data; thiazides lose natriuretic efficacy as GFR falls, so a loop agent replaces them in advanced CKD.
- Paradoxical uses: thiazides and amiloride reduce urine output in nephrogenic diabetes insipidus; amiloride is specifically the agent for lithium-induced nephrogenic DI because it blocks ENaC, the channel through which lithium enters principal cells.
- Diuretic resistance: distal tubule hypertrophy blunts loop diuretic response; adding a thiazide-type agent such as metolazone produces sequential nephron blockade — expect brisk diuresis and steep potassium and magnesium drops.
- Common distractors: a thiazide is the wrong answer in acute pulmonary edema (use IV loop diuretic); and never combine a potassium supplement with a potassium-sparing agent plus an ACE inhibitor without close potassium monitoring.